Citius Pharma(CTXR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ITIUS PHARMA Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update Granted FDA approval of LYMPHIR™ in treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024 under ticker CTOR Achieved primary and secondary endpoints of Mino-Lok Phase 3 Trial CRANFORD, N.J., August 12, 2024 -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the ...